Full text is available at the source.
A novel multiplex RPA/CRISPR-Cas12a integrated biosensor for on-site detection of high-risk HPV genotypes
New combined test for on-site detection of high-risk HPV types
AI simplified
Abstract
An integrated platform enables 100% concordance with qPCR for detecting eight key high-risk HPV genotypes in under 50 minutes.
- The platform combines multiplex recombinase polymerase amplification with CRISPR-Cas12a for sensitive detection.
- Single-copy sensitivity is achieved within 50 minutes at 37 °C, overcoming limitations of traditional methods.
- Clinical validation identified three additional low viral-load positives that conventional methods missed.
- The system allows for visual readout under UV light and does not require specialized equipment.
- This approach could facilitate accessible molecular diagnostics in resource-limited settings.
AI simplified